KPV: The Cleanest Rodent Data on This Desk, and No Human Trial at All

The short version

KPV is a tiny peptide — just three amino acids, lysine-proline-valine — that corresponds to the tail end of a natural hormone called alpha-MSH. In mice, it consistently calms intestinal inflammation in colitis models without producing the skin-darkening effect of its parent hormone, and it gets into gut-lining cells through a specific transporter that is turned up during inflammation, which is a genuinely elegant piece of biology.

The honest caveat, and the reason this page reads differently from most KPV marketing, is that every study behind that picture is in vitro or in an animal — chiefly mice. As of this writing, no published human clinical trial of KPV exists. That means there is no human dose, no human safety profile, and no human efficacy data to report — only a research chemical with a promising rodent story and an entirely open question about whether any of it translates to people.

What it is

KPV is the linear tripeptide lysine-proline-valine (Lys-Pro-Val), corresponding to residues 11 through 13 — the C-terminal end — of alpha-melanocyte-stimulating hormone (alpha-MSH). It is one of the smallest peptides discussed anywhere in this portfolio, small enough that its behavior in the body is governed less by receptor pharmacology in the conventional sense and more by how efficiently it can be absorbed and delivered intact before peptidases break it down.

That fragility is the central practical problem in the KPV literature. Free KPV is readily degraded by peptidases, and a meaningful share of the recent published research is not about KPV's biological effect at all, but about formulation engineering — nanoparticles, hydrogels, and targeted delivery systems designed to keep it intact long enough to reach inflamed tissue ^[11][12].

How it works

KPV retains the anti-inflammatory activity of its parent hormone, alpha-MSH, while lacking alpha-MSH's pigmentary (melanogenic) effect — the two functions of the parent molecule are pharmacologically separable, and KPV isolates the anti-inflammatory half. Mechanistically, it suppresses NF-kB and MAP-kinase inflammatory signaling and reduces the production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha ^[13].

A distinctive delivery mechanism sets KPV apart from most peptides on this desk: it is taken up directly into intestinal epithelial cells by the di/tripeptide transporter PepT1 (gene name SLC15A1), which is notably upregulated in inflamed gut tissue ^[13]. That means KPV's effect is, in principle, self-targeting — it is absorbed more where inflammation is worse — which is the biological rationale for the newer nanoparticle- and hydrogel-based oral delivery systems designed to exploit that same transporter ^[11][12].

What the research shows

PepT1-targeted nanodrug, mouse colitis. A 2024 study co-assembled KPV with the immunosuppressant FK506 into PepT1-targeted nanoparticles and found the combination improved outcomes in both acute and chronic DSS-induced colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond either drug given alone ^[11]. This is combination-formulation research in mice, not a KPV monotherapy human result.

Oral nanoparticle delivery, mouse colitis. Hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue and reduced colitis severity in mice more effectively than non-targeted formulations, with stronger prevention of mucosal damage and lower TNF-alpha ^[12]. Again, a mouse model, and delivery-system-focused.

Foundational mechanism paper. KPV enters human intestinal epithelial cells (in cell-culture lines) via PepT1, and nanomolar concentrations inhibit NF-kB and MAP-kinase activation and cytokine secretion in both epithelial and immune cells in vitro; the same paper found oral KPV reduced colitis severity in two different mouse models ^[13]. This is the mechanistic backbone the rest of the KPV literature builds on.

Independent colitis replication. A separate study found KPV reduced colonic inflammation in mice across two different colitis models, with earlier recovery, lower markers of tissue neutrophil activity, and reduced inflammatory infiltrate — and, notably, the effect held even in mice genetically lacking the melanocortin-1 receptor, indicating the anti-inflammatory action does not require that specific receptor ^[14]. This cross-model replication is one of the stronger pieces of evidence in the KPV file, and it is still entirely a mouse finding.

Review context. A comprehensive 2008 review situates KPV within a family of alpha-MSH-derived tripeptides showing anti-inflammatory activity across many animal models of disease, explicitly framing KPV as an anti-inflammatory alternative to alpha-MSH because it keeps the anti-inflammatory action while losing the pigmentary one ^[15]. It is a review, synthesizing findings like ^[11] through ^[14], not a new primary result.

Reported effects, cautions & safety

This site does not fabricate community-reported anecdotes where none have been documented, and — unlike CJC-1295, ipamorelin, semaglutide, and retatrutide — no meaningful, verifiable body of KPV-specific real-world-use reports exists in the sources this desk draws on. That absence is itself informative: KPV has a far smaller and more recent research-community footprint than the growth-hormone-axis or metabolic peptides on this desk, and this page will not invent a folklore of reported effects to fill the gap.

What can be said, honestly, comes from the published record itself rather than from anecdote. No published human clinical trial of KPV exists, so there is no human dosing regimen, no documented human side-effect profile, and no human safety data of any kind — a materially different situation from ipamorelin or CJC-1295, both of which at least have small human pharmacokinetic studies behind them ^[4][5][9]. Free KPV is a small, peptidase-labile molecule with no validated human pharmacokinetics; the active formulation research ^[11][12] exists precisely because the free peptide does not reliably survive long enough in the body to be useful without protection, which is itself a caution about any research-grade KPV product that does not address that stability problem. KPV is derived from alpha-MSH, and while its defining feature in the literature is that it lacks alpha-MSH's pigmentary action, it should not be conflated with melanocortin agonists marketed for tanning — the KPV research base is specifically about anti-inflammatory action, not pigmentation. Secondary web sources for KPV frequently carry citation errors, wrong identifiers copied from aggregator to aggregator; every identifier in this desk's KPV file was independently re-verified against the primary literature rather than copied secondhand. KPV is sold only as a research chemical for laboratory use and has no approved drug or dietary-supplement status anywhere.

Where it fits in the evidence hierarchy

KPV is the clearest illustration on this desk of a gap between mechanistic elegance and clinical evidence. Its core biology — a natural transporter that concentrates it where inflammation is worst, a cytokine-suppressing effect replicated across independent studies and multiple mouse colitis models ^[11][13][14] — is a genuinely tidy story. But it is a rodent and in-vitro story from beginning to end. CJC-1295 and ipamorelin at least have small human pharmacokinetic trials; semaglutide and retatrutide have large human efficacy trials. KPV has neither — which does not mean the mechanism is wrong, only that no one has yet tested whether it holds up in a person. See the comparison page for the full evidence-maturity picture.